Braidwell LP Sells 767,842 Shares of Sionna Therapeutics, Inc. $SION

Braidwell LP lowered its holdings in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 71.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 314,013 shares of the company’s stock after selling 767,842 shares during the period. Braidwell LP’s holdings in Sionna Therapeutics were worth $9,235,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in Sionna Therapeutics in the third quarter valued at approximately $30,000. BNP Paribas Financial Markets acquired a new stake in shares of Sionna Therapeutics during the 2nd quarter worth approximately $31,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at $45,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Sionna Therapeutics in the 3rd quarter valued at $147,000. Finally, Virtus Investment Advisers LLC acquired a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $96,000.

Insider Transactions at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 29,063 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total value of $1,295,628.54. Following the sale, the director owned 3,530,702 shares in the company, valued at $157,398,695.16. This represents a 0.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the sale, the insider owned 6,494,962 shares in the company, valued at $259,798,480. This represents a 3.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 382,368 shares of company stock valued at $15,898,607 over the last three months. Corporate insiders own 3.90% of the company’s stock.

Sionna Therapeutics Trading Up 1.7%

NASDAQ SION opened at $37.32 on Friday. The company has a market cap of $1.68 billion and a P/E ratio of -19.14. The company has a fifty day simple moving average of $38.53 and a 200 day simple moving average of $35.97. Sionna Therapeutics, Inc. has a 12-month low of $7.26 and a 12-month high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.15.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a report on Monday, December 1st. BTIG Research reiterated a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a report on Monday, March 2nd. Guggenheim increased their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Citigroup began coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating for the company. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 price target on shares of Sionna Therapeutics in a research note on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $50.57.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.